Insider trades
Paul B. Manning, Director of Candel Therapeutics CADL, has filed 14 purchases and 9 sales on the open market. Over the past 12 months that comes to a net purchase of $7.7M. The latest trade was on 06/23.
Paul B. Manning
Director
- Company
- Candel Therapeutics CADL
- First filing
- 23/06/21
- Trades
- 46 trades
- Buys / sales
- 14 / 9
- 12-month net buying
- $7.7M
- Last trade
- 06/23
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
LQDA | Open-market sale | 06/04 | 06/08 | 200,000 sh5 trades | $63.91avg. | $12,782,058.7 | −20.0% |
| Open-market buy | 02/23 | 02/26 | 550,458 sh | $5.45 | $2,999,996.1 | +24.9% | |
VRCA | Open-market buy | 25/11/25 | 25/11/25 | 4,126,142 sh2 trades | $4.24avg. | $17,494,842.08 | No record |
LQDA | Open-market sale | 25/08/28–25/09/02 | 25/09/02 | 670,837 sh4 trades | $28.26avg. | $18,957,475.28 | −60.9% |
| Open-market buy | 25/05/30 | 25/06/03 | 750,000 sh | $2.75 | $2,062,500 | +35.9% | |
CADL | Open-market buy | 24/12/16 | 24/12/18 | 1,250,000 sh2 trades | $6.00avg. | $7,500,000 | +2325.5% |
VRCA | Open-market buy | 24/11/22 | 24/11/26 | 22,921,348 sh2 trades | No stated value | No stated value | No record |
LiquidiaLQDA | Open-market buy | 24/09/12 | 24/09/16 | 337,078 sh | $8.90 | $2,999,994.2 | +70.3% |
| Open-market buy | 24/06/27 | 24/07/01 | 1,333,333 sh | $2.25 | $2,999,999.25 | No record | |
LiquidiaLQDA | Open-market buy | 23/12/14 | 23/12/18 | 279,330 sh | $7.16 | $2,000,002.8 | No record |
| Open-market buy | 23/11/17 | 23/11/20 | 100,000 sh | $1.63 | $163,000 | +0.6% | |
| Open-market buy | 23/08/16 | 23/08/16 | 16,466,667 sh | $0.90 | $14,820,000.3 | No record | |
| Open-market buy | 23/07/24 | 23/07/24 | 200,000 sh | $5.02 | $1,004,000 | +2.6% |
